Streetbeat News

Stock Prices

INTR

Inter & Co (NASDAQ:INTR) reported Q2 earnings per share of $0.09, beating the analyst estimate of $0.08 by 12.5%. Sales were $283.76M, surpassing the $275.46M estimate and marking a 22.14% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:20 pm

IONQ

IonQ has announced a breakthrough in partial error correction for quantum computing, which enhances the efficiency of running large applications on near-term quantum systems.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:20 pm

BTTR

Better Choice Company shares are trading higher after the company formed a special committee to evaluate M&A and asset monetization opportunities.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:19 pm

ACMR

ACM Research shares are trading higher after the company reported Q2 financial results and raised its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:17 pm

GHI

Greystone Housing Impact (NYSE:GHI) reported Q2 2024 earnings per share of $0.19, missing the analyst estimate of $0.40 by 52.5%. The company also reported sales of $21.969 million, missing the estimate of $26.487 million by 17.06%. This represents a 22.38% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:17 pm

SILO

Silo Pharma shares are trading higher after the company entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:15 pm

SILO

Silo Pharma has partnered with a global Contract Research Organization (CRO) to study the SPU-16 peptide's ability to target inflamed epithelium in an experimental autoimmune encephalomyelitis (EAE) model, commonly used for multiple sclerosis (MS). This partnership aims to explore the peptide's potential as a targeted drug delivery tool for spinal cord inflammation. Shares of Silo Pharma moved higher following the announcement.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:14 pm

ADV

Advantage Solutions (NASDAQ:ADV) reported Q2 2024 adjusted EPS of $(0.04), missing the $0.10 estimate by 140%. However, sales of $873.357M beat the $753.154M estimate by 15.96%, despite a 9.38% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:14 pm

WIX

Wix.com Ltd (NASDAQ:WIX) reported strong fiscal Q2 2024 results, with revenue and profit beating analyst estimates. Revenue grew 12% year-over-year to $435.7 million, and adjusted EPS was $1.67. The company saw significant growth in its Partner and Subscription segments. Wix expects continued growth in fiscal 2024 and has raised its revenue and free cash flow guidance.

Portfolio Pulse from Anusuya Lahiri

August 07, 2024 | 12:14 pm

ALNY

Alnylam Pharmaceuticals will present the HELIOS-B Phase 3 study results of Vutrisiran at the ESC Congress 2024. The topline results show a significant reduction in mortality and cardiovascular events. The company will host a conference call and investor webcast on August 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:14 pm